Associated equity: InMed Pharmaceuticals
Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
InMed Pharmaceuticals — 14 videos in collection
InMed Pharmaceuticals is a global leader in the manufacture and development of rare cannabinoids. Together with its recently acquired subsidiary, BayMedica, it has unparalleled cannabinoid manufacturing capabilities to serve a wide spectrum of consumer markets, including pharmaceutical and health and wellness.
In this video series, we’ll be introducing the BayMedica team, discussing the team members’ impressive careers and experience in the industry and what excites them about the InMed/BayMedica acquisition. Today’s video highlights Jim Kealy, VP of synthetic biology.
Get access to the very latest content matched to your personal investment style.